AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.73 and traded as high as $7.49. AngioDynamics shares last traded at $7.44, with a volume of 435,277 shares trading hands.
Analyst Ratings Changes
Several equities analysts have commented on the company. Canaccord Genuity Group dropped their target price on AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, October 4th. HC Wainwright reiterated a "buy" rating and set a $14.00 price target on shares of AngioDynamics in a research note on Friday, October 4th.
View Our Latest Research Report on ANGO
AngioDynamics Stock Performance
The company has a market cap of $290.13 million, a P/E ratio of -1.20 and a beta of 0.67. The business has a 50 day moving average price of $7.03 and a two-hundred day moving average price of $6.74.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. During the same quarter last year, the firm posted ($0.12) earnings per share. The firm's revenue was down 14.2% on a year-over-year basis. As a group, research analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current year.
Insider Activity
In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the firm's stock in a transaction on Monday, October 7th. The stock was acquired at an average price of $6.03 per share, with a total value of $120,600.00. Following the transaction, the chief executive officer now owns 681,582 shares in the company, valued at $4,109,939.46. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders acquired 22,568 shares of company stock worth $135,847. Insiders own 5.40% of the company's stock.
Institutional Trading of AngioDynamics
Several hedge funds have recently modified their holdings of the company. Systematic Financial Management LP increased its position in AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier's stock valued at $12,763,000 after acquiring an additional 162,972 shares during the last quarter. Millennium Management LLC raised its position in AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock valued at $10,850,000 after purchasing an additional 529,861 shares in the last quarter. Acadian Asset Management LLC grew its holdings in AngioDynamics by 11.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier's stock worth $5,940,000 after acquiring an additional 107,764 shares in the last quarter. Royce & Associates LP boosted its stake in shares of AngioDynamics by 10.8% during the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier's stock valued at $7,672,000 after purchasing an additional 96,138 shares in the last quarter. Finally, Segall Bryant & Hamill LLC raised its position in shares of AngioDynamics by 142.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock worth $7,091,000 after acquiring an additional 535,958 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.
AngioDynamics Company Profile
(
Get Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
See Also
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
